Financial Snapshot
What do Laboratory Corporation of America Holdings latest financial metrics show?
Mixed. The strongest factor is Q1 2026 revenue of $334B with operating profitability, while the main concern is leverage and weaker cash conversion.
For Q1 2026, this snapshot blends growth, profitability, cash generation, balance-sheet capacity, and capital efficiency. The result is mixed because demand and operating earnings look solid, but cash conversion has weakened and debt remains a heavier burden than cash.
For more context on Laboratory Corporation of America Holdings (LH): History, Ownership, Mission, How It Works & Makes Money, the first metric to study deeper is free cash flow.
Revenue and earnings quality
Is Laboratory Corporation of America Holdings revenue growth producing quality earnings?
Strong. Revenue growth is supported by operating income, net income, and diluted EPS confirmation, with the clearest support coming from Q1 2026 adjusted operating income of $4825M and full-year 2025 net income of $102B and diluted EPS of $1185.
Growth looks more durable than one-time. Investors compare revenue durability with operating income, net income, and EPS across compatible annual periods because quality is better when sales growth turns into real profit, not just a bigger top line. For Laboratory Corporation of America Holdings, recurring testing demand and earnings confirmation both matter.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $334B, 42% year-over-year, Q1 2026 | $1287B, 58% increase, full-year 2025 | Organic, with recurring diagnostic volume and stronger specialty testing mix | Looks repeatable because Laboratory Corporation of America Holdings serves over 160M patient encounters annually and processed approximately 650M tests in the preceding twelve months |
| Operating Income | $4825M, Q1 2026 adjusted operating income | Previous comparable value not provided | Growth direction is positive, but the prior-period comparison is unavailable | Still useful because operating income is rising alongside revenue, which points to operating leverage |
| Net Income | $102B, full-year 2025 | Previous comparable value not provided | Supported by verified operating performance; no unusual-item detail provided | Confirms that revenue growth reached bottom-line earnings |
| Diluted EPS | $1185, full-year 2025 | Previous comparable diluted EPS not provided | Share-count effect cannot be isolated from the supplied data | Shows shareholders received per-share earnings growth, not just higher revenue |
How durable is Laboratory Corporation of America Holdings revenue?
The strongest durability signal is recurring diagnostic volume, supported by over 160M patient encounters and approximately 650M tests in the preceding twelve months. The biggest visibility limit is concentration in diagnostics, even though multi-year contracts represent approximately 500% of revenue.
- Demand Quality: Recurring testing demand is high because patients, physicians, and health systems keep using diagnostics; that makes revenue more visible than one-time project work.
- Pricing and Volume: Specialty testing demand increased by 70% year-over-year versus routine testing growth of 25%; the split between price and volume is not provided.
- Diversification: Laboratory Corporation of America Holdings Diagnostics contributes approximately 750% of total company revenue and Biopharma Laboratory Services contributes 250%; multi-year contracts represent approximately 500% of revenue.
That mix should support cash conversion if margins keep holding.
Cash and margins
Is Laboratory Corporation of America Holdings profitable after capex and shareholder returns?
Laboratory Corporation of America Holdings kept profitability strong, with 144% adjusted operating margin in Q1 2026 and $4825M adjusted operating income, but cash generation weakened. Full-year 2025 profit remained positive, yet $4650M of capex and a $598M quarterly dividend tested how much earnings stayed available after reinvestment and payouts.
Gross margin is not supplied here, so the cleaner read is on operating and net results. Laboratory Corporation of America Holdings reported $102B net income in full-year 2025 and $1185 diluted EPS, while inflationary wage and supply pressure of 120 basis points and $150M higher interest expense acted as headwinds. A 35% specialty genomic test list price increase helped offset that pressure.
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | Unavailable in supplied data. | Unavailable in supplied data. | No verified gross margin input was provided. | Product economics cannot be measured from the supplied data. |
| Operating Margin | 144% in Q1 2026. | Unavailable in supplied data. | Adjusted operating income of $4825M and pricing help from the 35% specialty genomic test list price increase. | Scale appears to support operating efficiency, even with cost pressure. |
| Net Margin | Unavailable in supplied data. | Unavailable in supplied data. | Full-year 2025 net income of $102B and diluted EPS of $1185 show bottom-line profit, but no net margin was given. | Final profitability is positive, but the margin rate cannot be verified here. |
| Operating Cash Flow | Unavailable; 2026-03-31 operating cash flow growth was -6882%. | Unavailable. | Working-capital effects are not detailed, but the sharp decline shows earnings did not translate cleanly into cash. | Accounting profit was not matched by stronger cash conversion in that period. |
| Free Cash Flow | Unavailable. | Unavailable. | $4650M of full-year 2025 capex, mainly for IT infrastructure and laboratory automation, reduced residual cash. | After reinvestment, less cash was left for debt reduction, buybacks, or extra dividends. |
What most affects Laboratory Corporation of America Holdings cash conversion?
The biggest factor is heavy reinvestment, especially $4650M of 2025 capex, plus weaker 2026 operating cash flow growth of -6882%. That points to a cash conversion challenge that looks partly structural because it is tied to IT and automation spending.
- Main Driver: Capex for IT infrastructure and laboratory automation is the main drag; it looks structural, not temporary.
- Evidence Gap: The supplied data does not break out working-capital changes or exact free cash flow.
- Metric to Monitor: Watch operating cash flow and free cash flow in 2026, plus dividend coverage.
Balanced Liquidity
Can Laboratory Corporation of America Holdings support its obligations and investment needs from its balance sheet?
Mixed. Cash helps, but the $4321M cash balance does not fully offset the primary solvency concern from $524B of total debt. Liquidity is serviceable, but refinancing and debt service still matter, especially with variable-rate interest expense pressure.
Cash is only one part of the picture. For Laboratory Corporation of America Holdings, the balance sheet also depends on working capital, asset quality, debt service, solvency, liquidity, and refinancing access. The latest movement indicators show debt growth of 044%, asset growth of 378%, book value per share growth of 151%, receivables growth of 123%, and inventory growth of -692%.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | Cash and Cash Equivalents of $4321M as of March 31, 2026; receivables growth of 123%; inventory growth of -692%. | Mixed | Near-term obligations look manageable, but the cash cushion alone does not remove operating or refinancing pressure. |
| Total and Net Debt | Total Debt of $524B; management’s leverage framework targets a net debt-to-EBITDA ratio of 25x to 30x. | Mixed | Leverage is the main constraint and can limit flexibility if earnings soften. |
| Debt Service and Refinancing | Interest expense increased by $150M from variable-rate debt exposure. | Mixed | Debt service is still covered, but higher financing costs can squeeze future cash flow. |
| Asset Quality | Asset growth of 378%; book value per share growth of 151%; receivables growth of 123%; inventory growth of -692%. | Mixed | Asset expansion supports scale, but receivables and financing sensitivity need monitoring. |
| Liabilities and Equity | Latest total liabilities and shareholders' equity were not provided in the prompt. | Mixed | Without the full capital base, investors should focus on debt burden and cash generation. |
Which balance-sheet risk matters most for Laboratory Corporation of America Holdings?
The biggest risk is leverage and refinancing pressure, led by $524B of total debt and a $150M interest expense increase from variable-rate exposure. Cash provides a cushion, but it does not erase financing risk.
- Current Exposure: Cash and Cash Equivalents of $4321M versus Total Debt of $524B as of March 31, 2026.
- Protection: Management’s net debt-to-EBITDA framework of 25x to 30x and available cash liquidity.
- Warning Signal: Watch further increases in interest expense and debt growth, especially if liquidity tightens; the investor profile context is also useful at Exploring Laboratory Corporation of America Holdings (LH) Investor Profile: Who's Buying and Why?.
Capital Efficiency
Does Laboratory Corporation of America Holdings (LH) earn adequate returns while funding growth?
Mixed. Labcorp’s capital efficiency looks reasonable, but not clearly strong, because heavy reinvestment is still driving growth and shareholder returns while leverage remains meaningful. Internal cash appears likely to cover a large part of reinvestment needs, but not all of the expansion and payout burden.
Return quality at Labcorp has to be judged alongside leverage, asset intensity, capital expenditure, working capital needs, and external funding. In lab services, returns can look acceptable even when cash is tied up in automation, acquisitions, and network expansion, so the real question is whether operating cash flow can keep funding growth without stretching the balance sheet. For background on the business model, see Laboratory Corporation of America Holdings (LH): History, Ownership, Mission, How It Works & Makes Money.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable in the supplied data. | Operating margins and recurring cash generation should be strong enough to justify ongoing reinvestment, but no ROIC figure was provided. | Investors cannot verify whether invested capital is creating operating value from the given inputs alone. |
| ROE and ROA | Unavailable in the supplied data. | No ROE or ROA values were provided, so leverage and asset-intensity effects cannot be separated numerically here. | Shareholder returns may benefit from leverage, but that does not prove underlying asset efficiency. |
| Maintenance and Growth Investment | Full-year 2025 Capital Expenditures of $4650M; R&D Expense of $1654M for the preceding twelve months; $12B allocated for acquisitions over the preceding twelve months; $2375M BioReference Health laboratory asset acquisition. | The spending mix shows both sustaining investment and expansion, with acquisitions playing a major role in growth. | Labcorp is putting substantial capital into automation, innovation, and geographic and specialty expansion. |
| Internal Funding Capacity | 2026 share repurchase authorization of $10B; Q1 2026 quarterly cash dividend of $072 per share, totaling $598M; common shares outstanding of 8321M shares; 2026-03-31 Weighted Average Shares Growth of -024% and Weighted Average Shares Diluted Growth of -036%; leverage target of 25x to 30x. | Cash generation likely funds a meaningful share of reinvestment, but buybacks, dividends, acquisitions, and capex together still leave leverage as an important constraint. | Internal funding appears partial rather than fully self-contained, so flexibility depends on staying near the stated leverage target. |
Are Laboratory Corporation of America Holdings (LH) returns on capital sustainable?
Mostly yes if cash flow stays strong. The strongest durability driver is reinvestment in automation, specialty testing, and acquisitions; the main weakness is that high capex, M&A spending, and shareholder payouts can pressure returns if leverage rises above the target.
- Operating Source: Margin support comes from lab scale, automation, and specialty testing mix.
- Funding Requirement: The largest verified capital need is acquisition and expansion spending, including $12B and $4650M in 2025 capex.
- Durability Test: Returns would weaken if cash flow no longer covers reinvestment and leverage moves beyond the 25x to 30x target.
Financial Resilience
How resilient is Laboratory Corporation of America Holdings, and which warning signs matter most?
Mixed. The main buffer is Labcorp’s diversified diagnostics platform and operating flexibility. The most important verified warning sign is reimbursement risk, because Medicare and Medicaid account for approximately 140% of total company revenue and further Medicare cuts under PAMA could follow if the moratorium is not extended beyond December 31, 2026.
Labcorp can still defend liquidity and essential investment, but resilience weakens if reimbursement, labor costs, or partner concentration starts to press margins at the same time. The company’s operational fixes, including alternative courier routing and corrective actions after the Texas power failure involving approximately 500 specimens, help, but they do not remove policy and volume risk.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Lower reimbursement can squeeze operating leverage, reduce earnings, and weaken cash flow and debt capacity. | Diversified diagnostics operations and a 0% update to the Clinical Laboratory Fee Schedule for most tests on January 01, 2026 offer near-term stability. | Slowing revenue growth, lower adjusted operating margin, or weaker cash flow would confirm deterioration. |
| Working-Capital or Investment Pressure | Higher labor expense, receivables timing, or expansion spending can absorb cash that would otherwise fund capex and service needs. | Improved staffing trends, including the global minimum wage increase for entry-level phlebotomists and lab technicians and the 200 basis point year-over-year decrease in employee turnover, support internal funding capacity. | Rising operating cash outflow, weaker cash conversion, or faster asset growth would be the key signal. |
| Interest or Refinancing Pressure | Higher debt costs or maturities would reduce free cash flow and limit financing flexibility. | Monitor leverage discipline and existing liquidity, especially if net debt-to-EBITDA stays controlled. | Higher net debt-to-EBITDA, tighter liquidity, or refinancing stress would show rising pressure. |
Which financial warning signs should investors monitor at Laboratory Corporation of America Holdings?
The two strongest signals are reimbursement pressure and margin compression; both are confirmed risks if revenue or adjusted operating margin weakens. Partner concentration is the third risk to watch, because it can turn into revenue volatility if major contracts are terminated.
Reimbursement Cuts and PAMA Exposure
Medicare and Medicaid reimbursement is the clearest near-term risk. If the moratorium is not extended beyond December 31, 2026, Labcorp could face lower rates, so revenue growth, payer mix, and adjusted operating margin matter most.
Labor Cost Pressure
Shortages of clinical laboratory scientists and phlebotomists can raise operating costs. The offset is better retention, but investors should still track turnover, wage pressure, and labor-driven margin movement.
Health System Partner Concentration
Testing volume is concentrated among a small number of health system partners, so contract loss could hit revenue quickly. Labcorp’s logistics rerouting and Texas corrective actions show operating resilience, but contract retention remains the key metric.
Mixed Scorecard
What does Labcorp’s financial health mean for investors?
Labcorp earns a Mixed overall rating. The strongest factor is revenue quality, while the weakest is debt and reimbursement exposure. The most important condition for the investment case is whether recurring test demand can keep converting into cash despite leverage and working-capital pressure.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Strong | Strong demand is visible in $12.87B full-year 2025 revenue, 58% growth over 2024, and $3.34B Q1 2026 revenue with 42% year-over-year growth. |
| Profitability and Cash | Mixed | 14.4% Q1 2026 adjusted operating margin and $1.02B full-year 2025 net income are positive, but weak operating cash flow and free cash flow growth hurt cash conversion. |
| Balance Sheet and Liquidity | Mixed | $4321M cash supports liquidity, but $524B total debt limits flexibility and makes refinancing and interest cost more important to watch. |
| Capital Efficiency | Mixed | $4650M capex, $12B acquisition spending, $10B buyback authorization, and dividends all require disciplined capital allocation and steady funding. |
| Financial Resilience | Mixed | Recurring demand helps resilience, but PAMA, labor, interest cost, and concentration risk can still pressure margins, cash flow, and investor confidence. |
- What Supports the Thesis: Strong recurring test volume and specialty demand support durable revenue quality and make the business easier to model.
- What Challenges the Thesis: Leverage, reimbursement exposure, and weak cash conversion create the biggest uncertainty for earnings durability.
- What to Monitor: Revenue growth, adjusted operating margin, and net debt-to-EBITDA are the three decision-useful indicators.
For readers comparing this scorecard with Laboratory Corporation of America Holdings (LH): History, Ownership, Mission, How It Works & Makes Money, the next step is testing how revenue, margins, and leverage hold up across forecast scenarios and valuation assumptions.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
Is Labcorp's operating margin improving in 2026?
Q1 2026 Adjusted Operating Margin was 144%, supported by Q1 2026 Adjusted Operating Income of $4825M Investors should compare future quarters before calling the trend durable, especially because wage and supply inflation created a 120 basis point operating margin headwind
How much cash does Labcorp hold against debt?
Labcorp reported Cash and Cash Equivalents of $4321M and Total Debt of $524B as of March 31, 2026 That cash balance supports liquidity, but the debt load remains the main balance sheet concern for investors
Can Labcorp keep funding dividends and buybacks?
Labcorp paid a quarterly cash dividend of $072 per share, totaling $598M for Q1 2026, and announced a 2026 share repurchase authorization of $10B Sustainability depends on cash generation, capex, acquisition spending, and leverage discipline
What risks could pressure Labcorp's resilience?
Key financial resilience risks include potential PAMA reimbursement cuts after December 31, 2026, shortages of clinical laboratory scientists and phlebotomists, testing-volume concentration among health system partners, and operational disruptions Mitigations include contracts, routing flexibility, training, and retention initiatives
Does Labcorp's revenue quality support financial health?
Revenue quality looks supportive because Labcorp serves over 160M patient encounters annually and processed approximately 650M tests during the preceding twelve months Specialty testing grew 70% year-over-year, faster than routine testing growth of 25%, which helps the mix